Steminent Biotherapeutics Inc. (TPEX:7729)
Taiwan
· Delayed Price · Currency is TWD 78.50
-4.20 (-5.08%)
Apr 29, 2026, 2:00 PM CST
Steminent Biotherapeutics Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Cash & Equivalents | 499.18 | 205.4 | 451.86 | 153.43 | 230.56 | Upgrade
|
| Short-Term Investments | - | 11.6 | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 499.18 | 217 | 451.86 | 153.43 | 230.56 | Upgrade
|
| Cash Growth | 130.03% | -51.98% | 194.50% | -33.45% | 464.90% | Upgrade
|
| Other Receivables | 0.73 | 0.94 | 0.84 | 0.33 | 0.78 | Upgrade
|
| Receivables | 0.73 | 0.94 | 0.84 | 0.33 | 0.78 | Upgrade
|
| Inventory | 15.06 | 12 | 7.67 | 3.48 | 10.4 | Upgrade
|
| Prepaid Expenses | 2.89 | 5.82 | - | - | 1.14 | Upgrade
|
| Other Current Assets | - | - | 6.09 | 3.91 | - | Upgrade
|
| Total Current Assets | 517.86 | 235.76 | 466.46 | 161.15 | 242.88 | Upgrade
|
| Property, Plant & Equipment | 149.35 | 168.18 | 83.16 | 58.87 | 22.8 | Upgrade
|
| Other Intangible Assets | 1.78 | 2.39 | 0.51 | 0.32 | 0.16 | Upgrade
|
| Other Long-Term Assets | 29.51 | 30.34 | 43.74 | 15.31 | 13.66 | Upgrade
|
| Total Assets | 698.49 | 436.66 | 593.88 | 235.65 | 279.5 | Upgrade
|
| Accounts Payable | 2.85 | 2.54 | 2.15 | 1.93 | 0.65 | Upgrade
|
| Accrued Expenses | 11.58 | 11.41 | 13.81 | 10.11 | 10.01 | Upgrade
|
| Current Portion of Leases | 14.2 | 13.68 | 13.15 | 7.17 | 7.9 | Upgrade
|
| Current Unearned Revenue | - | - | - | 0.46 | 1.09 | Upgrade
|
| Other Current Liabilities | 9.52 | 4.09 | 9.55 | 4.46 | 2.85 | Upgrade
|
| Total Current Liabilities | 38.15 | 31.73 | 38.66 | 24.12 | 22.5 | Upgrade
|
| Long-Term Debt | 21.67 | - | - | - | - | Upgrade
|
| Long-Term Leases | 37.5 | 50.09 | 62.23 | 48 | 11.27 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 0.03 | 0.15 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 1.46 | Upgrade
|
| Total Liabilities | 97.34 | 81.97 | 100.89 | 72.11 | 35.23 | Upgrade
|
| Common Stock | 666.34 | 560.45 | 557.95 | 444.94 | 444.94 | Upgrade
|
| Additional Paid-In Capital | 710.51 | 581.43 | 580.17 | 239.16 | 239.16 | Upgrade
|
| Retained Earnings | -988.31 | -814.27 | -655.53 | -526.3 | -440.82 | Upgrade
|
| Comprehensive Income & Other | 212.61 | 27.09 | 10.39 | 5.74 | 0.99 | Upgrade
|
| Shareholders' Equity | 601.15 | 354.7 | 492.99 | 163.54 | 244.27 | Upgrade
|
| Total Liabilities & Equity | 698.49 | 436.66 | 593.88 | 235.65 | 279.5 | Upgrade
|
| Total Debt | 73.36 | 63.78 | 75.38 | 55.16 | 19.17 | Upgrade
|
| Net Cash (Debt) | 425.81 | 153.23 | 376.48 | 98.27 | 211.39 | Upgrade
|
| Net Cash Growth | 177.90% | -59.30% | 283.12% | -53.51% | - | Upgrade
|
| Net Cash Per Share | 7.22 | 2.74 | 7.77 | 2.21 | 6.00 | Upgrade
|
| Filing Date Shares Outstanding | 66.63 | 56.05 | 55.8 | 44.49 | 44.49 | Upgrade
|
| Total Common Shares Outstanding | 66.63 | 56.05 | 55.8 | 44.49 | 44.49 | Upgrade
|
| Working Capital | 479.71 | 204.03 | 427.8 | 137.03 | 220.38 | Upgrade
|
| Book Value Per Share | 9.02 | 6.33 | 8.84 | 3.68 | 5.49 | Upgrade
|
| Tangible Book Value | 599.37 | 352.31 | 492.47 | 163.22 | 244.11 | Upgrade
|
| Tangible Book Value Per Share | 9.00 | 6.29 | 8.83 | 3.67 | 5.49 | Upgrade
|
| Machinery | 109.69 | 99.07 | 42.81 | 34.07 | 32.36 | Upgrade
|
| Leasehold Improvements | 79.08 | 79.08 | 41.5 | 41.05 | 40.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.